Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer

Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in psychedelics, named chair of Reset Pharmaceuticals’ Scientific Advisory Board NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) — Reset Pharmaceuticals, Inc. (Reset Pharma) a privately-held biotechnology company…

Source